Navigation Links
Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
Date:11/1/2007

NEW YORK, Nov. 1 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) today announced the results of a double-blind, randomized, placebo-controlled clinical trial, published in the November 2007 issue of the Journal of Clinical Hypertension, which demonstrated that nebivolol significantly reduced sitting diastolic and systolic blood pressure used as monotherapy among African-American patients with stage I-II hypertension. The study also found that nebivolol was well tolerated in comparison to placebo, with a low incidence of traditional beta blocker side effects, such as fatigue, sexual dysfunction, and depression. In addition, nebivolol was not associated with adverse changes in blood lipids and glucose levels. Nebivolol, a novel beta blocker, is currently under review by the U.S. Food and Drug Administration for the treatment of hypertension.

African Americans have an increased prevalence of high blood pressure, develop elevated blood pressure earlier in life, and have higher rates of hypertension-related death from stroke, heart disease, and end-stage kidney disease. Although awareness of hypertension in African Americans has increased in recent years, their control rates (blood pressure <140/90 mm/Hg) remain low at approximately 30 percent.

"The findings of this study are important considering the excessive burden of high blood pressure in African Americans and the need for new treatment options," explains Elijah Saunders, MD, lead investigator of the study and professor of medicine and Head, Section of Hypertension at the University of Maryland School of Medicine. "Advances like this in the beta blocker class are particularly important because African Americans have an historically poor resp
'/>"/>

SOURCE Forest Laboratories, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure as Long-Term Monotherapy and in Combination Therapy
2. Rapid Whole Blood Testing for Infectious Mononucleosis Antibodies
3. Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing
4. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
5. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
6. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
7. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
8. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
9. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
10. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
11. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)...  The annual customer satisfaction survey of over 5,700 ... #1 across all specialties. Every year, Florida ... poll of EHR users and publishes an internationally recognized ... Praxis EMR topped 348 other systems, with the ... used by Black Book. In addition to earning the ...
(Date:5/29/2015)... BOSTON , May 29, 2015 ... automation, and contract manufacturing, and Vaxxas , a ... delivery technology, have been named winners of the 2015 ... Jet Coating Instrument , an advanced technology platform to ... The award was announced last evening at the Good ...
(Date:5/29/2015)... , May 29, 2015  Haemonetics Corporation (NYSE: ... , Chief Operating Officer, will present at the JMP ... on June 23 rd , 2015 at ... access Mr. Davies, presentation live via webcast at: ... (NYSE: HAE ) is a global healthcare company ...
Breaking Medicine Technology:Praxis EMR Ranks #1 for Physician Satisfaction in Black Book's 2015 Survey of Solo and Small Practices 2Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 2Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 3
... superDimension, Ltd. ® , a privately-owned company that develops ... received FDA 510(k) clearance for the superDimension marker delivery ... Company,s Electromagnetic Navigational Bronchoscopy (ENB) system, which has treated ... David S. Wilson, MD, Columbus Regional Hospital, ...
... 2011 Medstreaming, a leading provider of medical ... fully integrated Cardiovascular PACS and certified EMR with ... components to its Cardiovascular Information System (CVIS) platform, ... offer a FDA-cleared PACS and EMR certified for ...
Cached Medicine Technology:superDimension Receives FDA 510(k) Clearance for Marker Delivery Kit 2superDimension Receives FDA 510(k) Clearance for Marker Delivery Kit 3superDimension Receives FDA 510(k) Clearance for Marker Delivery Kit 4Medstreaming Launches Fully Integrated Cardiovascular PACS and Certified EMR With Electronic Whiteboard at ACC 2Medstreaming Launches Fully Integrated Cardiovascular PACS and Certified EMR With Electronic Whiteboard at ACC 3
(Date:5/30/2015)... May 30, 2015 Promising clinical trial ... (ASCO) Annual Meeting 2015 show activity of the investigational ... case specifically against brain metastases and in another case ... patients. , "I am thrilled to have been able ... early 40s. She didn't have any other great treatment ...
(Date:5/30/2015)... May 30, 2015 On Thursday, ... Dr. Charles Simone and Dr. Evan Alley both ... ‘Meet the Mesothelioma Experts’ series. The interview was ... mesothelioma centers of excellence. Drs. Simone and Alley ... Mary Hesdorffer, with whom they discussed the mesothelioma ...
(Date:5/30/2015)... 30, 2015 Nicole Blodgett, Vice ... Income Associate (DIA) designation to further her expertise ... is designed for insurance advisors, health care professionals, ... knowledge and expertise associated with the risk and ... designation is only the latest accomplishment in Nicole's ...
(Date:5/30/2015)... May 30, 2015 San Luis ... she is offering a free analysis and consultation for ... coincides with Disability Awareness Month, which was created by ... across the United States such as Polk recognize the ... awareness about the possibility of disability, as well as ...
(Date:5/30/2015)... A live auction will be held to ... surgery centers and other medical facilities around the United ... radiology, surgery, endoscopy, lab, anesthesia, exam and much more. ... June 2nd starting at 10:00am EDT. The equipment is ... Hiatus Rd., Sunrise, FL 33351. Anyone can participate ...
Breaking Medicine News(10 mins):Health News:ONT-380 has Stage IV HER2+ Breast Cancer Patient 'Worrying About Normal Stuff Again' 2Health News:ONT-380 has Stage IV HER2+ Breast Cancer Patient 'Worrying About Normal Stuff Again' 3Health News:Interview with Mesothelioma Experts, Drs. Simone and Alley Now Available on Demand 2Health News:Secura Consultants Expands Disability Insurance Expertise 2Health News:San Luis Obispo Insurance Agent Susan Polk Offering Complementary Insurance Analysis In Honor Of Disability Awareness Month 2Health News:Centurion to Sell Surplus Medical Equipment in Online and On-site Auction 2
... in Stopping their Periods, But Unsure,About Medical Implications, ... in a national survey say that they are interested ... sure if it,s safe. Yet when,physicians are polled, 97 ... is, in fact, medically safe and,acceptable. The survey results ...
... AIRES, Argentina, October 3, 2007 The first reported ... more than two-thirds of patients with moderate to severe ... achieved at least a 75 percent reduction in psoriasis ... as measured by the Psoriasis Area and Severity Index ...
... has received a five-year, $8.4 million grant from the ... survey the genetic, physical and behavioral profiles of children ... reach and ethnic diversity of the Autism Genetic Resource ... overseen by Clara Lajonchere, research assistant professor at the ...
... The Stop & Shop Supermarket,Company, Giant Food and General ... for the Cure with the Pink for the Cure Program. ... Shop/Giant,Consumer Advisor Andrea Astrachan, "and by purchasing ,Pink for the ... the fight against,breast cancer and help us donate to this ...
... Genaera,s Strategic Focus on Core Programs in Obesity ... Genaera,Corporation (Nasdaq: GENR ) today announced ... the July 2007 option to acquire from,Genaera the ... as a,drug. Pexiganan is a novel, small peptide ...
... California Nurses,Association/National Nurses Organizing Committee today condemned President,Bush,s veto ... Insurance,Program. "Listening to the overheated rhetoric coming out ... be gone but his legacy lives on," said Zenei,Cortez, ... chastised,Bush for his recent claims that legislators who passed ...
Cached Medicine News:Health News:Safe to Stop the Flow?: Differing Attitudes Found Between Women and Doctors Concerning Menstrual Suppression 2Health News:Safe to Stop the Flow?: Differing Attitudes Found Between Women and Doctors Concerning Menstrual Suppression 3Health News:Promising Phase 3 trial results show biologic therapy ustekinumab significantly improved psoriasis 2Health News:Promising Phase 3 trial results show biologic therapy ustekinumab significantly improved psoriasis 3Health News:Promising Phase 3 trial results show biologic therapy ustekinumab significantly improved psoriasis 4Health News:USC granted $8.4 million for autism research 2Health News:USC granted $8.4 million for autism research 3Health News:Stop & Shop and Giant Food Join General Mills in Pink for the Cure 2Health News:Genaera Corporation Announces Licensing of Exclusive Rights to Pexiganan, a Novel Anti-Infective Drug Candidate, by Macrochem Corporation 2Health News:Genaera Corporation Announces Licensing of Exclusive Rights to Pexiganan, a Novel Anti-Infective Drug Candidate, by Macrochem Corporation 3Health News:Genaera Corporation Announces Licensing of Exclusive Rights to Pexiganan, a Novel Anti-Infective Drug Candidate, by Macrochem Corporation 4Health News:California Nurses Association Blasts Bush for Veto on Children's Health 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: